DALLAS--(Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Medicis Pharmaceutical Corporation (NYSE: MRX) in connection with a buyout for $44 per share to Valeant Pharmaceuticals International. Concerned MRX investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or firstname.lastname@example.org about their rights and remedies.)--Securities lawyers at
“At least one analyst has set a target price for the company’s stock at $45.00. Our potential lawsuit will ascertain whether the company has been adequately and fairly shopped”
“At least one analyst has set a target price for the company’s stock at $45.00. Our potential lawsuit will ascertain whether the company has been adequately and fairly shopped,” said Hamilton Lindley. “We will seek to ensure that all relevant information is disclosed and the highest price is paid so that shareholder interests are protected in terms of price and information.”
Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide, with no costs paid by shareholders. MRX stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at email@example.com or 877-583-2855 with questions or concerns.